PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Samarium”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Neutron powder diffraction with (nat)Sm: crystal structures and magnetism of a binary samarium deuteride and a ternary samarium magnesium deuteride.

Binary SmH(3) (trigonal, a=656.7(3), c=680.1(3) pm, P$\bar 3$c1, Z=6), ternary SmMg2H7 (tetragonal, a=626.47(6), c=937.2(2) pm, P4(1)2(1)2, Z=4) and the corresponding deuterides SmD3 (a=653.9(1)m, c=676.7(2) pm) and SmMg2D7 (a=624.10(1), c=934.81(2) pm) have been prepared by hydrogenation (deuteration) of elemental samarium and the Laves phase SmMg2, respectively, and investigated by X-ray and neutron powder diffraction and SQUID and vibration magnetometry. The problem of the enormous neutron absorption of the natural isotopic mixture (natSm) is circumvented by carefully choosing the neutron wavelength (approximately 50 pm) and the use of double-walled cylindrical sample holders and a high-intensity neutron diffractometer (D4c at ILL). SmD3 crystallises with a tysonite-type structure and has three independently ordered deuterium atom sites with trigonal-planar, trigonal-pyramidal and tetrahedral metal environments and Sm--D bond lengths in the range 220(1)-258(1) pm (average: 235 pm). SmMg2D7 is a new deuteride that crystallises with an LaMg2D7-type structure. It displays four fully occupied deuterium sites having triangular and tetrahedral metal environments and Sm--D bond lengths in the range 227.6(5)-246.8(8) pm (average: 239 pm). These are the first samarium-deuterium bond lengths to be reported. Both deuterides are paramagnetic down to 2 K (SmD3: mueff=0.63(1) muB, thetap approximately -4 K; SmMg2D7: mueff=0.57(2) muB, thetap approximately -4 K). Their crystal structures and chemical and physical properties suggest mainly ionic bonding according to the limiting ionic formulae Sm3+(H-)3 and Sm3+(Mg2+)2(H-)7.

Journal Article↗

Samarium(III) carbenoid as a competing reactive species in samarium-promoted cyclopropanation reactions.

The trivalent samarium carbenoid I2SmCH2I-promoted cyclopropanation reactions with ethylene have been investigated and are predicted to be highly reactive, similarly to the divalent samarium carbenoid ISmCH2I. The methylene transfer and carbometalation pathways were explored and compared with and without coordination of THF solvent molecules to the carbenoid. The methylene transfer was found to be favored, with the barrier to reaction going from 12.9 to 9.2 kcal/mol compared to barriers of 15.4-17.5 kcal/mol for the carbometalation pathway upon the addition of one THF molecule.

Journal Article↗

Samarium(II)-mediated pinacol coupling in water: occurrence of unexpected disproportionation and action of low-valent samarium as an active species.

[reaction: see text] Mechanistic studies of one-electron reduction in water using samarium were carried out. Unexpected disproportionation in water was observed via UV-vis spectroscopic analysis. This fact indicates that low-valent samarium species can exist in water. Furthermore, the SmCl(3)-Sm and SmCl(3)-Mg systems were found to act as good one-electron reducing agents in water.

Journal Article↗

Preparation and pharmacokinetics of samarium(III)-153-labeled DTPA-bis-biotin. Characterization and theoretical studies of the samarium(III)-152 conjugate.

The complex(153)Sm(III)DTPA-bis-biotin was prepared with a 99% radiochemical purity and a specific activity of 370 MBq/mg employing a molar ratio of DTPA-bis-biotin/Sm from 2 to 4 at pH 8.0. In vitro studies demonstrated that the complex is stable after dilution in saline and in human serum. Avidity of labeled biotin for avidin was not affected by the labeling procedure. Pharmacokinetic data of (153)Sm(III)DTPA-bis-biotin in normal mice showed that blood clearance is biexponential during the time interval from 0 to 24 h and that 3 h postinjection 92 +/- 4.32% of the dose is eliminated in the urine. To have further evidence which could sustain that (153)Sm(III)DTPA-bis-biotin is stable in solution as a real coordination complex, (152)Sm(III)DTPA-bis-biotin was obtained in macroscopic quantities and its characterization was done by IR, TGA, and conductivity measurements. The results indicated that the complex was chemically pure, where the Sm(3+) ion is neutralized by three carboxylate groups of the DTPA-bis-biotin ligand and coordinated to it. Using the Force Field method followed by ab initio calculations, the DTPA-bis-biotin and the Sm(III)DTPA-bis-biotin molecules were done. Accordingly, the coordination sphere of Sm(III) was totally satisfied with nitrogen and oxygen donors; the best coordination number was 9. The conformation geometry of both compounds is presented.

Analysis of Variance↗

Bond valence sums in coordination chemistry. The calculation of the oxidation state of samarium in complexes containing samarium bonded only to oxygen.

A simple method is presented for calculating the oxidation state of Sm in complexes where Sm is bonded only to O ligands. A total of 88 SmO(n)() fragments with n = 4-12 were retrieved from the Cambridge Structural Database and were analyzed using the bond valence sum (BVS) method. New R(0) values for Sm(II)-O of 2.116(21) A and for Sm(III)-O of 2.055(13) A were derived. The average R(0) value of 2.086 A gives a good approximation of the oxidation state of the Sm ion, either +2 or +3, from the observed distances without any assumptions. The Sm-O distances for +2 and +3 complexes with coordination numbers of 4-11 are tabulated and reflect the requirement that the BVS must equal the oxidation state. The distances for CN = 12 were not included because of problems with the reported crystal structures. Several X-ray structure determinations where the BVS and the oxidation state did not agree are discussed.

Journal Article↗

[A dynamic observation on the fate of samarium in mouse liver].

It is generally considered that the rare earth compounds are plasma membrane-impermeable, thus affecting the cells only on their surface. Recently, we found that after repeated injections to mice of large dose of samarium trichloride, a soluble compound of rare earth, samarium aggregates appeared in Kupffer cells and hepatocytes of liver. In this study, we aimed at observing the route by which samarium enters the liver cells and the process of the formation of samarium aggregates. Samarium trichloride was given to Swiss mice at one dose of 70 mg/kg intravenously. Thereafter, at different intervals from 15 min to 48 h after the injection, the samarium in liver was traced dynamically by electron microscopy and X ray microanalysis. From 15 min to 2 h both Kupffer cells and hepatocytes endocytosed samarium-containing particles and formed phagosomes, in which the ingested particles were progressively concentrated. Besides, the small phagosomes fused with each other. Phagocytosis was especially active in Kupffer cells. During the 4 h to 24 h many Kupffer cells were degenerated and broken. In hepatocytes the phagosomes gathered mostly around the bile canaliculi. Groups of highly electron-dense particles were found in the lumen of bile canaliculi, implying the excretion of samarium by bile. At the 48 h, the samarium-containing phagosomies were found still in both kinds of cells in the liver.

Animals↗

[Rapid reduction of a variety of organic functionalities including a new selective reduction with samarium diiodide].

This review deals with the rapid reduction of a variety of organic functionalities, including a new selective reduction of carboxylic acid, with samarium diiodide in the presence of additives under mild conditions. The single electron donor ability of samarium diiodide can be enhanced with ligands around Sm2+ when sufficient electrons are supplied from the ligands. Mechanistic consideration of this enhancement led to our finding that carboxylic acid, ester, amide, nitrile, pyridine and other functionalities were rapidly reduced with samarium diiodide in the presence of a base, acid, water and methanol as ligands at room temperature in good yields. Particularly, these systems directly reduced carboxylic acid into alcohol and a samarium diiodide--85% phosphoric acid system immediately reduced an aromatic primary amide to aldehyde in good yield. Pyridines were reduced to piperidines with a samarium diiodide-base or water system in excellent yields; also, the aromatic nucleus of phenol derivatives was rapidly reduced with a samarium diiodide-base system. Furthermore, these organic functionalities were rapidly reduced with an Sm or Yb metal-hydrochloric acid system. Aliphatic and aromatic carboxylic acids with a coexisting aldehyde or that bearing a formyl group were selectively reduced to the corresponding alcohols with a new samarium diiodide-samarium triflate-methanol-base or water system within a few minutes at room temperature in good to almost quantitative yield.

Amides↗

[Study on the spectroscopy and electrochemistry of the combination between samarium (III) ion probe and bovine serum albumin].

The synthesis of solid compound of bovine serum albumin (BSA) with samarium (III) ion was studied. The FTIR spectrum shows that samarium (III) ion forms high sensitivity compound with BSA's oxygen in hydroxyl and nitrogen in amidocyanogen or amide groups. The ultraviolet spectrum shows that samarium (III) ion binds directly with residue of tyrosine. The character of the combination between samarium (III) ion and BSA was studied under simulated physiology conditions. The fluorescence spectrum shows that the molar ratio of samarium (III) ion to BSA is 2.5:1, with apparent complex constant lgK = 11.00. By cyclic voltammetry, the paper reports the stability of compound of BSA with samarium (III) ion and the effect pH on the of combination between samarium (III) ion and BSA.

Animals↗

Mechanistic aspects of samarium-mediated sigma-bond activations of arene C-H and arylsilane Si-C bonds.

To investigate the potential role of Sm-Ph species as intermediates in the samarium-catalyzed redistribution of PhSiH3 to Ph2SiH2 and SiH4, the samarium phenyl complex [Cp*2SmPh]2 (1) was prepared by oxidation of Cp2*Sm (2) with HgPh2. Compound 1 thermally decomposes to yield benzene and the phenylene-bridged disamarium complex Cp*2Sm(mu-1,4-C6H4)SmCp*2 (3). This decomposition reaction appears to proceed through dissociation of 1 into monomeric Cp*2SmPh species which then react via unimolecular and bimolecular pathways, involving rate-limiting Cp* metalation and direct C-H activation, respectively. The observed rate law for this process is of the form: rate = k1[1] + k2[1]2. Complex 1 efficiently transfers its phenyl group to PhSiH3, with formation of Ph2SiH2 and [Cp*2Sm(mu-H)]2 (4). Quantitative Si-C bond cleavage of C6F5SiH3 is effected by the samarium hydride complex 4, yielding silane and [Cp*2Sm(mu-C6F5)]2 (5). In contrast, Si-H activation takes place upon reaction of 4 with o-MeOC6H4SiH3, affording the samarium silyl species [structure: see text] Cp*2SmSiH2(o-MeOC6H4) (7). Complex 7 rapidly decomposes to [Cp*2Sm(mu-o-MeOC6H4)]2 (6) and other samarium-containing products. Compounds 5 and 6 were prepared independently by oxidation of 2 with Hg(C6F5)2 and Hg(o-MeOC6H4)2, respectively. The mechanism of samarium-mediated redistribution at silicon, and chemoselectivity in sigma-bond metathesis reactions, are discussed.

Journal Article↗

Samarium 153Sm lexidronam.

Samarium 153Sm lexidronam is a medium energy beta-emitting radioisotope chelated to the tetraphosphate, ethylenediaminetetramethylenephosphonic acid (EDTMP). 153Sm has a physical half-life of 1.9 days. Samarium 153Sm lexidronam concentrates in bone tissue and has a metastatic lesion: normal bone ratio of 4. Clearance of nonskeletal radioactivity after administration of samarium 153Sm lexidronam is rapid, and is almost complete from the blood and urine within 1 and 6 hours, respectively. Some degree of pain relief was achieved in 72% of patients with bone metastases after a single dose of samarium 153Sm lexidronam 1 mCi/kg (37 MBq/kg) compared with 44% of placebo recipients (p < 0.025). Relief was generally attained within 2 weeks and lasted for a median of 8 to 15 weeks. After recurrence of pain, a second dose of samarium 153Sm lexidronam may produce further pain relief in some patients. The dose-limiting toxicity of samarium 153Sm lexidronam is reversible myelosuppression.

Analgesics, Non-Narcotic↗

Regioselective samarium diiodide induced couplings of carbonyl compounds with 1,3-diphenylallene and alkoxyallenes: a new route to 4-hydroxy-1-enol ethers.

Since its introduction into synthetic organic chemistry, samarium diiodide has found broad application in a variety of synthetically important transformations. Herein, we describe the first successful intermolecular additions of samarium ketyls to typical allenes such as 1,3-diphenylallene (7), methoxyallene (12) and benzyloxyallene (25). Reaction of different samarium ketyls with 1,3-diphenylallene (7) occurred exclusively at the central carbon atom of the allene to afford products 9 in moderate to good yields. In contrast, reductive coupling of cyclic ketones to methoxyallene (12) regioselectively provided 4-hydroxy-1-enol ethers 13, which derive from addition to the terminal allene carbon atom of 12, in moderate to good yields. Whereas the E/Z selectivity with respect to the enol ether double bond is low, excellent diastereoselectivity has been observed in certain cases with regard to the ring configuration (e.g. compound 13 b). Studies with deuterated tetrahydrofuran and alcohol were performed to gain information about the reaction mechanism of this coupling process, which involves alkenyl radicals. The couplings of samarium ketyls derived from acyclic ketones and aldehydes gave lower yields, and in several cases cyclopentanols 20 are formed as byproducts. Branched acyclic ketones and conformationally more flexible cyclic ketones such as cycloheptanone led to a relatively high amount of cyclopentanol derivatives 20, whose formation involves an intramolecular hydrogen atom transfer through a geometrically favoured six-membered transition state followed by a cyclization step. The samarium diiodide mediated addition of 8 b to benzyloxyallene (25) afforded the expected enol ethers 26, albeit in only low yield. Additionally, spirocyclic compounds 27 and 28 were obtained, which are formed by a cascade reaction involving an addition/cyclization sequence. In the novel coupling process described here methoxyallene (12) serves as an equivalent of acrolein. The 1,4-dioxygenated products obtained contain a masked aldehyde functionality and are therefore valuable building blocks in organic synthesis.

Journal Article↗

Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation.

We report the simultaneous use of europium-DTPA (Eu-DTPA) and samarium-DTPA (Sm-DTPA) in cytotoxicity experiments to analyze simultaneously LAK and NK cell lysis and to differentiate between specific target lysis and bystander killing. The target cells were either labelled with Eu-DTPA or Sm-DTPA chelates by electroporation, which permits the use of target cell lines or primary leukemic B cells (B-CLL) that cannot be labelled by the conventional dextran-sulphate method. The release of europium and samarium reaches a maximum at comparable time intervals (2-3 h). Due to the shorter counting interval within the samarium window the labelling efficiency is about ten times less efficient compared to europium. Using europium as label for the LAK target Daudi and samarium as label for the NK sensitive cell line K562 the differentiation of LAK versus NK activity can be performed in a single culture assay. Also, the killing of B cells and bystander cells by cytotoxic T cells was analyzed in a system where T cells were redirected to B cells through CD3 x CD19 bispecific antibodies. In fact, no bystander killing was noted when bispecific antibodies were used to bridge cytotoxic T cells to the B cells. This approach provides a simple non-radioactive method for evaluating cytotoxicity against two different cells in a single culture well.

Cell Line↗

Structure of human uridine-cytidine kinase 2 determined by SIRAS using a rotating-anode X-ray generator and a single samarium derivative.

Uridine-cytidine nucleoside kinase 2 (UCK2) is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway. UCK2 catalyzes the phosphorylation of the natural ribonucleosides cytidine and uridine to cytidine 5'-monophosphate (CMP) and uridine 5'-monophosphate (UMP), respectively, and activates several important frontline antimetabolite drugs. The present contribution reports the rapid crystal structure determination of human UCK2 complexed with a magnesium ion and the reaction products adenosine 5'-diphosphate (ADP) and CMP. Diffraction data were collected on a copper rotating-anode X-ray generator from one native UCK2 crystal and a single samarium-derivative crystal. Utilizing the relatively high anomalous signal from the samarium derivative at the Cu Kalpha wavelength, the structure was determined by single isomorphous replacement and single anomalous signal (SIRAS) phasing techniques. Two of the four major samarium sites are located in the active sites of the two UCK2 molecules that form the asymmetric unit and appear to displace the magnesium ions present in the native crystals. The crystal structures of UCK2 alone and in complex with various ligands have recently been determined using traditional multiple isomorphous replacement (MIR) phasing techniques and data from three heavy-atom derivatives. The reported structures validate our independently determined structure. Of more than 1000 kinase crystal structure entries in the Protein Data Bank, less than 1% of them have been determined by SIRAS. For the published kinase crystal structures determined by SIRAS, all data were reportedly collected at various synchrotron-radiation facilities. This study demonstrates that diffraction data collected from a single samarium derivative using Cu Kalpha radiation provides sufficient phasing power to determine a novel macromolecular crystal structure.

Crystallography, X-Ray↗

ppt level detection of samarium(III) with a coated graphite sensor based on an antibiotic.

N-[2-[4-[[[(Cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl pyrazine carboxamide (glipizid) was explored as an electro-active material for preparing a polymeric membrane-based sensor selective to samarium ions. The membrane incorporated 30% poly(vinyl chloride) (PVC), 53% benzyl acetate (BA), 11% glipizid and 6% sodium tetraphenyl borate. When coated on the surface of a graphite electrode, it exhibits Nernstian responses in the concentration range of 1.0 x 10(-5) to 1.0 x 10(-10) M, with a detection limit of 8.0 x 10(-11)M samarium. The electrode shows high selectivity towards samarium over several cations (alkali, alkaline earth, transition and heavy metal ions), and specially lanthanide ions. The proposed sensor has a very short response time (< 15 s), and can be used in a wide pH range for at least ten weeks. It was used as an indicator electrode in potentiometric titration of Sm(III) ions with an EDTA solution, and for determination of samarium in binary and ternary mixtures.

Anti-Bacterial Agents↗

Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.

Various radioisotopes conjugated to pyrophosphate analogues have been developed for systemic metabolic radiotherapy. Samarium-153-EDTMP is a 1:1 complex of radioactive Samarium-153 and a Tetraphosphonate [ethylenediamine-tetramethylene phosphonic acid (EDTMP)]. Samarium Sm-153-EDTMP has a high affinity for skeletal tissue and concentrates by chemiabsorption in areas of enhanced metabolic activity, where it associates with the hydroxyapatite crystal. Samarium-153 Lexidronam [Quadramet (R)] has been approved for routine use by the FDA. This agent offers several advantages over other agents used for palliating bone pain. Due to its half-life of 46 hours and its beta emissions, a high dose rate can be delivered to regions adjacent to enhanced osteoblastic activity over a short period of time with little residual long term activity being left in the bone marrow. This paper summarizes both animal studies and clinical studies performed with this agent. Special emphasis will be given to the pivotal Phase-III clinical studies and subsequent studies performed since its approval by the FDA. Special considerations regarding appropriate selection of patients, preparation, follow-up of patients and adjustments to the usual recommended dose [1 mCi/kg (35 Mbq/kg)] will be discussed. Current and future treatment options utilizing Sm-153-EDTMP with other pharmaceuticals appear promising and will substantially extend its use into new areas. In addition, because it also emits a 103 keV gamma ray which makes it suitable for imaging and assessment of biodistribution, dosimetric applications are possible in the future.

Analgesics, Non-Narcotic↗

Heteroleptic Lanthanide Complexes with Aryloxide Ligands. Synthesis and Structural Characterization of Divalent and Trivalent Samarium Aryloxide/Halide and Aryloxide/Cyclopentadienide Complexes.

Synthesis of a new class of heteroleptic samarium aryloxide complexes has been achieved by the use of homoleptic samarium(II) bis(aryloxide) Sm(OAr)(2)(THF)(3) (1, Ar = C(6)H(2)Bu(t)(2)-2,6-Me-4) as a starting material, which is easily obtained by reaction of Sm(N(SiMe(3))(2))(2)(THF)(2) with 2 equiv of ArOH in THF. 1 reacts with 1 equiv of SmI(2) in THF to give Sm(II) mixed aryloxide/iodide [(ArO)Sm(&mgr;-I)(THF)(3)](2) (2), which adopts a dimeric structure via very weak Sm.I (3.534(2) Å) interactions. Reaction of 2 with C(5)Me(5)K in THF/HMPA affords the corresponding Sm(II) aryloxide/cyclopentadienide (C(5)Me(5))Sm(OAr)(HMPA)(2) (3). Oxidation of 1 with 0.5 equiv of I(2) in THF gives monomeric samarium(III) aryloxide/iodide (ArO)(2)SmI(THF)(2) (4), while the similar reaction of 1 with ClCH(2)CH(2)Cl or (t)BuCl in THF affords dimeric samarium(III) aryloxide/chloride [(ArO)(2)Sm(&mgr;-Cl)(THF)](2) (5). Crystal data for 1: monoclinic, space group P2(1), a = 9.903(3) Å, b = 16.718(5) Å, c = 13.267(2) Å, beta = 95.17(2) degrees, V = 2187(2) Å(3), Z = 2, D(c) = 1.223 g cm(-)(3), R = 0.0634. Crystal data for 2.2THF: monoclinic, space group P2(1)/a, a = 18.330(6) Å, b = 14.320(4) Å, c = 13.949(3) Å, beta = 103.16(2) degrees, V = 3563(2) Å(3), Z = 2, D(c) = 1.46 g cm(-)(3), R = 0.0606. Crystal data for 3: triclinic, space group P&onemacr;, a = 10.528(1) Å, b = 12.335(2) Å, c = 19.260(2) Å, alpha = 101.33(1) degrees, beta = 95.230(9) degrees, gamma = 108.54(1) degrees, V = 2293.1(5) Å(3), Z = 2, D(c) = 1.25 g cm(-)(3), R = 0.0358. Crystal data for 4: monoclinic, space group C2/c, a = 17.191(7) Å, b = 10.737(6) Å, c = 21.773(7) Å, beta = 98.80(3) degrees, V = 3971(3) Å(3), Z = 4, D(c) = 1.44 g cm(-)(3), R = 0.0467. Crystal data for 5: monoclinic, space group P2(1)/n, a = 13.750(3) Å, b = 17.231(3) Å, c = 14.973(6) Å, beta = 95.81(2) degrees, V = 3529(2) Å(3), Z = 2, D(c) = 1.31 g cm(-)(3), R = 0.0557.

Journal Article↗

Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.

PURPOSE: The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. METHODS: Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months after treatment. Pain was evaluated using a subjective scale (from 0 to 10) before and for 8 weeks after the treatment. Blood counts were obtained before treatment and once a week for 2 months during follow-up. Dosimetry, based upon the urinary excretion of the isotope, was estimated in 41 individuals, and the resulting radiation absorbed doses were correlated with hematological data. RESULTS: Reduction in pain scores of 75% to 100% was obtained in 36 patients (49%), with a decrease of 50% to 75%, 25% to 50%, and 0% to 25% in, respectively, 20 (27%), 10 (14%), and 7 (10%) patients. There was no significant relationship between the pain response and location of the primary tumor (breast or prostate cancer). Mild to moderate myelosuppression was noted in 75.3% of patients, usually with hematological recovery at 8 weeks. The mean bone marrow dose was 347 +/- 65 cGy, and only a weak correlation was found between absorbed dose and myelosuppression (Pearson coefficient = .4). CONCLUSIONS: Samarium-153-EDTMP is a valuable method for metastatic bone pain palliation. A mild to moderate and transitory myelosuppression is the main toxicity observed after samarium therapy, showing a weak correlation with dosimetric measures.

Adult↗